BACKGROUND: The value of regular surveillance for breast cancer in women with a genetic or familial predisposition to breast cancer is currently unproven. We compared the efficacy of magnetic resonance imaging (MRI) with that of mammography for screening in this group of high-risk women. METHODS: Women who had a cumulative lifetime risk of breast cancer of 15 percent or more were screened every six months with a clinical breast examination and once a year by mammography and MRI, with independent readings. The characteristics of the cancers that were detected were compared with the characteristics of those in two different age-matched control groups. RESULTS: We screened 1909 eligible women, including 358 carriers of germ-line mutations. Within a median follow-up period of 2.9 years, 51 tumors (44 invasive cancers, 6 ductal carcinomas in situ, and 1 lymphoma) and 1 lobular carcinoma in situ were detected. The sensitivity of clinical breast examination, mammography, and MRI for detecting invasive breast cancer was 17.9 percent, 33.3 percent, and 79.5 percent, respectively, and the specificity was 98.1 percent, 95.0 percent, and 89.8 percent, respectively. The overall discriminating capacity of MRI was significantly better than that of mammography (P<0.05). The proportion of invasive tumors that were 10 mm or less in diameter was significantly greater in our surveillance group (43.2 percent) than in either control group (14.0 percent [P<0.001] and 12.5 percent [P=0.04], respectively). The combined incidence of positive axillary nodes and micrometastases in invasive cancers in our study was 21.4 percent, as compared with 52.4 percent (P<0.001) and 56.4 percent (P=0.001) in the two control groups. CONCLUSIONS: MRI appears to be more sensitive than mammography in detecting tumors in women with an inherited susceptibility to breast cancer. Copyright 2004 Massachusetts Medical Society
BACKGROUND: The value of regular surveillance for breast cancer in women with a genetic or familial predisposition to breast cancer is currently unproven. We compared the efficacy of magnetic resonance imaging (MRI) with that of mammography for screening in this group of high-risk women. METHODS:Women who had a cumulative lifetime risk of breast cancer of 15 percent or more were screened every six months with a clinical breast examination and once a year by mammography and MRI, with independent readings. The characteristics of the cancers that were detected were compared with the characteristics of those in two different age-matched control groups. RESULTS: We screened 1909 eligible women, including 358 carriers of germ-line mutations. Within a median follow-up period of 2.9 years, 51 tumors (44 invasive cancers, 6 ductal carcinomas in situ, and 1 lymphoma) and 1 lobular carcinoma in situ were detected. The sensitivity of clinical breast examination, mammography, and MRI for detecting invasive breast cancer was 17.9 percent, 33.3 percent, and 79.5 percent, respectively, and the specificity was 98.1 percent, 95.0 percent, and 89.8 percent, respectively. The overall discriminating capacity of MRI was significantly better than that of mammography (P<0.05). The proportion of invasive tumors that were 10 mm or less in diameter was significantly greater in our surveillance group (43.2 percent) than in either control group (14.0 percent [P<0.001] and 12.5 percent [P=0.04], respectively). The combined incidence of positive axillary nodes and micrometastases in invasive cancers in our study was 21.4 percent, as compared with 52.4 percent (P<0.001) and 56.4 percent (P=0.001) in the two control groups. CONCLUSIONS: MRI appears to be more sensitive than mammography in detecting tumors in women with an inherited susceptibility to breast cancer. Copyright 2004 Massachusetts Medical Society
Authors: M D Dorrius; R M Pijnappel; M C van der Weide Jansen; L Jansen; P Kappert; M Oudkerk; P E Sijens Journal: Eur Radiol Date: 2011-11-11 Impact factor: 5.315
Authors: Kathryn P Lowry; Janie M Lee; Chung Y Kong; Pamela M McMahon; Michael E Gilmore; Jessica E Cott Chubiz; Etta D Pisano; Constantine Gatsonis; Paula D Ryan; Elissa M Ozanne; G Scott Gazelle Journal: Cancer Date: 2011-09-20 Impact factor: 6.860
Authors: Deirdre A Hill; Jennifer S Haas; Robert Wellman; Rebecca A Hubbard; Christoph I Lee; Jennifer Alford-Teaster; Karen J Wernli; Louise M Henderson; Natasha K Stout; Anna N A Tosteson; Karla Kerlikowske; Tracy Onega Journal: J Gen Intern Med Date: 2017-12-06 Impact factor: 5.128
Authors: Sana Parsian; Habib Rahbar; Kimberly H Allison; Wendy B Demartini; Matthew L Olson; Constance D Lehman; Savannah C Partridge Journal: Radiology Date: 2012-10-02 Impact factor: 11.105
Authors: Habib Rahbar; Zheng Zhang; Thomas L Chenevert; Justin Romanoff; Averi E Kitsch; Lucy G Hanna; Sara M Harvey; Linda Moy; Wendy B DeMartini; Basak Dogan; Wei T Yang; Lilian C Wang; Bonnie N Joe; Karen Y Oh; Colleen H Neal; Elizabeth S McDonald; Mitchell D Schnall; Constance D Lehman; Christopher E Comstock; Savannah C Partridge Journal: Clin Cancer Res Date: 2019-01-15 Impact factor: 12.531
Authors: Robin T Zon; Elizabeth Goss; Victor G Vogel; Rowan T Chlebowski; Ismail Jatoi; Mark E Robson; Dana S Wollins; Judy E Garber; Powel Brown; Barnett S Kramer Journal: J Clin Oncol Date: 2008-12-15 Impact factor: 44.544